<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Brain</journal-id>
      <journal-id journal-id-type="iso-abbrev">Brain</journal-id>
      <journal-id journal-id-type="publisher-id">brainj</journal-id>
      <journal-title-group>
        <journal-title>Brain</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0006-8950</issn>
      <issn pub-type="epub">1460-2156</issn>
      <publisher>
        <publisher-name>Oxford University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">35293990</article-id>
      <article-id pub-id-type="pmc">9420018</article-id>
      <article-id pub-id-type="doi">10.1093/brain/awac081</article-id>
      <article-id pub-id-type="publisher-id">awac081</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
        <subj-group subj-group-type="category-taxonomy-collection">
          <subject>AcademicSubjects/MED00310</subject>
          <subject>AcademicSubjects/SCI01870</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Biallelic <italic toggle="yes">CACNA2D1</italic> loss-of-function variants cause early-onset developmental epileptic encephalopathy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Dahimene</surname>
            <given-names>Shehrazade</given-names>
          </name>
          <aff>
<institution>Department of Neuroscience Physiology and Pharmacology, University College London (UCL)</institution>, <addr-line>London WC1E 6BT</addr-line>, <country country="GB">UK</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>von Elsner</surname>
            <given-names>Leonie</given-names>
          </name>
          <aff>
<institution>Institute of Human Genetics, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>20246 Hamburg</addr-line>, <country country="DE">Germany</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holling</surname>
            <given-names>Tess</given-names>
          </name>
          <aff>
<institution>Institute of Human Genetics, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>20246 Hamburg</addr-line>, <country country="DE">Germany</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mattas</surname>
            <given-names>Lauren S</given-names>
          </name>
          <aff>
<institution>Neurology and Neurological Sciences, Pediatrics, Division of Medical Genetics, Stanford University and Lucile Packard Children's Hospital</institution>, <addr-line>Palo Alto, CA 94304</addr-line>, <country country="US">USA</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pickard</surname>
            <given-names>Jess</given-names>
          </name>
          <aff>
<institution>Department of Neuroscience Physiology and Pharmacology, University College London (UCL)</institution>, <addr-line>London WC1E 6BT</addr-line>, <country country="GB">UK</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4496-244X</contrib-id>
          <name>
            <surname>Lessel</surname>
            <given-names>Davor</given-names>
          </name>
          <aff>
<institution>Institute of Human Genetics, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>20246 Hamburg</addr-line>, <country country="DE">Germany</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pilch</surname>
            <given-names>Kjara S</given-names>
          </name>
          <aff>
<institution>Department of Neuroscience Physiology and Pharmacology, University College London (UCL)</institution>, <addr-line>London WC1E 6BT</addr-line>, <country country="GB">UK</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kadurin</surname>
            <given-names>Ivan</given-names>
          </name>
          <aff>
<institution>Department of Neuroscience Physiology and Pharmacology, University College London (UCL)</institution>, <addr-line>London WC1E 6BT</addr-line>, <country country="GB">UK</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pratt</surname>
            <given-names>Wendy S</given-names>
          </name>
          <aff>
<institution>Department of Neuroscience Physiology and Pharmacology, University College London (UCL)</institution>, <addr-line>London WC1E 6BT</addr-line>, <country country="GB">UK</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6708-5323</contrib-id>
          <name>
            <surname>Zhulin</surname>
            <given-names>Igor B</given-names>
          </name>
          <aff>
<institution>Department of Microbiology and Translational Data Analytics Institute, The Ohio State University</institution>, <addr-line>Columbus, OH, 43210</addr-line>, <country country="US">USA</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dai</surname>
            <given-names>Hongzheng</given-names>
          </name>
          <aff>
<institution>Department of Molecular and Human Genetics, Baylor College of Medicine/NGS-Molecular, Baylor Genetics</institution>, <addr-line>Houston, TX</addr-line>, <country country="US">USA</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hempel</surname>
            <given-names>Maja</given-names>
          </name>
          <aff>
<institution>Institute of Human Genetics, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>20246 Hamburg</addr-line>, <country country="DE">Germany</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ruzhnikov</surname>
            <given-names>Maura R Z</given-names>
          </name>
          <aff>
<institution>Neurology and Neurological Sciences, Pediatrics, Division of Medical Genetics, Stanford University and Lucile Packard Children's Hospital</institution>, <addr-line>Palo Alto, CA 94304</addr-line>, <country country="US">USA</country></aff>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8494-8963</contrib-id>
          <name>
            <surname>Kutsche</surname>
            <given-names>Kerstin</given-names>
          </name>
          <aff>
<institution>Institute of Human Genetics, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>20246 Hamburg</addr-line>, <country country="DE">Germany</country></aff>
          <xref rid="awac081-FM1" ref-type="author-notes"/>
          <xref rid="awac081-cor2" ref-type="corresp"/>
          <!--kkutsche@uke.de-->
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4626-4856</contrib-id>
          <name>
            <surname>Dolphin</surname>
            <given-names>Annette C</given-names>
          </name>
          <aff>
<institution>Department of Neuroscience Physiology and Pharmacology, University College London (UCL)</institution>, <addr-line>London WC1E 6BT</addr-line>, <country country="GB">UK</country></aff>
          <xref rid="awac081-FM1" ref-type="author-notes"/>
          <xref rid="awac081-cor1" ref-type="corresp"/>
          <!--a.dolphin@ucl.ac.uk-->
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="awac081-cor1">Correspondence to: Annette C. Dolphin Department of Neuroscience Physiology and Pharmacology University College London (UCL) Gower St., London WC1E 6BT, UK E-mail: <email>a.dolphin@ucl.ac.uk</email></corresp>
        <corresp id="awac081-cor2">Correspondence may also be addressed to: Kerstin Kutsche Institute of Human Genetics University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany E-mail: <email>kkutsche@uke.de</email></corresp>
        <fn id="awac081-FM1">
          <p>Kerstin Kutsche and Annette C Dolphin contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="epub" iso-8601-date="2022-03-16">
        <day>16</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>16</day>
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <volume>145</volume>
      <issue>8</issue>
      <fpage>2721</fpage>
      <lpage>2729</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>11</month>
          <year>2021</year>
        </date>
        <date date-type="rev-recd">
          <day>26</day>
          <month>1</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>2</month>
          <year>2022</year>
        </date>
        <date date-type="corrected-typeset">
          <day>20</day>
          <month>7</month>
          <year>2022</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement>
        <copyright-year>2022</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="awac081.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>Voltage-gated calcium (Ca<sub>V</sub>) channels form three subfamilies (Ca<sub>V</sub>1&#x2013;3). The Ca<sub>V</sub>1 and Ca<sub>V</sub>2 channels are heteromeric, consisting of an &#x3B1;<sub>1</sub> pore-forming subunit, associated with auxiliary Ca<sub>V</sub>&#x3B2; and &#x3B1;<sub>2</sub>&#x3B4; subunits. The &#x3B1;<sub>2</sub>&#x3B4; subunits are encoded in mammals by four genes, <italic toggle="yes">CACNA2D1</italic>&#x2013;<italic toggle="yes">4</italic>. They play important roles in trafficking and function of the Ca<sub>V</sub> channel complexes. Here we report biallelic variants in <italic toggle="yes">CACNA2D1</italic>, encoding the &#x3B1;<sub>2</sub>&#x3B4;-1 protein, in two unrelated individuals showing a developmental and epileptic encephalopathy. Patient 1 has a homozygous frameshift variant c.818_821dup/p.(Ser275Asnfs*13) resulting in nonsense-mediated mRNA decay of the <italic toggle="yes">CACNA2D1</italic> transcripts, and absence of &#x3B1;<sub>2</sub>&#x3B4;-1 protein detected in patient-derived fibroblasts. Patient 2 is compound heterozygous for an early frameshift variant c.13_23dup/p.(Leu9Alafs*5), highly probably representing a null allele and a missense variant c.626G&gt;A/p.(Gly209Asp). Our functional studies show that this amino-acid change severely impairs the function of &#x3B1;<sub>2</sub>&#x3B4;-1 as a calcium channel subunit, with strongly reduced trafficking of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> to the cell surface and a complete inability of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> to increase the trafficking and function of Ca<sub>V</sub>2 channels. Thus, biallelic loss-of-function variants in <italic toggle="yes">CACNA2D1</italic> underlie the severe neurodevelopmental disorder in these two patients. Our results demonstrate the critical importance and non-interchangeability of &#x3B1;<sub>2</sub>&#x3B4;-1 and other &#x3B1;<sub>2</sub>&#x3B4; proteins for normal human neuronal development.</p>
      </abstract>
      <abstract abstract-type="teaser">
        <p>Dahimene <italic toggle="yes">et al.</italic> report biallelic pathogenic variants in <italic toggle="yes">CACNA2D1</italic>, encoding a calcium channel subunit &#x3B1;2&#x3B4;-1, in two unrelated individuals with developmental epileptic encephalopathy. One has a homozygous frameshift variant; the other is compound heterozygous for a frameshift and a missense variant rendering &#x3B1;2&#x3B4;-1 non-functional.</p>
      </abstract>
      <kwd-group>
        <kwd>epileptic encephalopathy</kwd>
        <kwd>calcium channel</kwd>
        <kwd>loss-of-function</kwd>
        <kwd>biallelic variants</kwd>
        <kwd>
          <italic toggle="yes">CACNA2D1</italic>
        </kwd>
      </kwd-group>
      <funding-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>Wellcome Trust</institution><institution-id institution-id-type="doi">10.13039/100010269</institution-id></institution-wrap>
</funding-source>
          <award-id>206279\Z\17\Z</award-id>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap>
</funding-source>
          <award-id>1R35GM131760</award-id>
        </award-group>
        <award-group award-type="grant">
          <funding-source>
<institution-wrap><institution>Deutsche Forschungsgemeinschaft</institution><institution-id institution-id-type="doi">10.13039/501100001659</institution-id></institution-wrap>
</funding-source>
          <award-id>1240/6-2</award-id>
          <award-id>1240/10-1</award-id>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="awac081-s1">
      <title>Introduction</title>
      <p>Voltage-gated calcium (Ca<sub>V</sub>) channels are present in all excitable cells including neurons, and open following membrane depolarization, allowing Ca<sup>2+</sup> entry.<sup><xref rid="awac081-B1" ref-type="bibr">1</xref></sup> The &#x3B1;1 pore-forming subunits are encoded by a family of 10 mammalian genes, divided into three subfamilies (Ca<sub>V</sub>1&#x2013;3).<sup><xref rid="awac081-B1" ref-type="bibr">1</xref></sup> In neurons, Ca<sub>V</sub>2 channels are mainly presynaptic and involved in synaptic transmission.<sup><xref rid="awac081-B2" ref-type="bibr">2</xref></sup></p>
      <p>The Ca<sub>V</sub>1 and Ca<sub>V</sub>2 subfamilies are associated with auxiliary Ca<sub>V</sub>&#x3B2; and &#x3B1;<sub>2</sub>&#x3B4; subunits.<sup><xref rid="awac081-B2" ref-type="bibr">2</xref></sup> The &#x3B1;<sub>2</sub>&#x3B4; proteins are encoded by four mammalian genes, <italic toggle="yes">CACNA2D1&#x2013;4</italic>,<sup><xref rid="awac081-B2" ref-type="bibr">2</xref></sup> encoding an &#x3B1;<sub>2</sub>&#x3B4; pre-protein that is post-translationally cleaved into two polypeptides, &#x3B1;<sub>2</sub> and &#x3B4;.<sup><xref rid="awac081-B3" ref-type="bibr">3</xref></sup> These extracellular glycoproteins remain disulphide-bonded together, linked into the plasma membrane by a glycosylphosphatidyl-inositol anchor.<sup><xref rid="awac081-B4" ref-type="bibr">4</xref></sup> Human &#x3B1;<sub>2</sub>&#x3B4;-1 pre-protein (P54289, UniProt) has 1103 amino acids. In conjunction with &#x3B2;, the &#x3B1;<sub>2</sub>&#x3B4; subunits play important roles in trafficking and function of Ca<sub>V</sub>1 and Ca<sub>V</sub>2 channels.<sup><xref rid="awac081-B5" ref-type="bibr">5</xref></sup></p>
      <p>Evidence that &#x3B1;<sub>2</sub>&#x3B4; proteins are involved in neurological disease has been reviewed recently.<sup><xref rid="awac081-B6" ref-type="bibr">6</xref></sup> Initial evidence was for &#x3B1;<sub>2</sub>&#x3B4;-2, and came from the spontaneous <italic toggle="yes">Cacna2d2</italic> mouse mutant strains including <italic toggle="yes">ducky</italic>,<sup><xref rid="awac081-B7" ref-type="bibr">7</xref></sup> which demonstrate absence epilepsy and severe cerebellar ataxia when both alleles are mutated. This reflects the strong expression of &#x3B1;<sub>2</sub>&#x3B4;-2 in particular neurons, specifically cerebellar Purkinje cells.<sup><xref rid="awac081-B7" ref-type="bibr">7</xref></sup> In humans, biallelic <italic toggle="yes">CACNA2D2</italic> variants cause a phenotypic spectrum ranging from congenital ataxia with cerebellar vermian atrophy on brain imaging<sup><xref rid="awac081-B8" ref-type="bibr">8</xref></sup> to cerebellar atrophy and developmental and epileptic encephalopathies (DEEs).<sup><xref rid="awac081-B9" ref-type="bibr">9</xref>,<xref rid="awac081-B10" ref-type="bibr">10</xref></sup> DEEs are characterized by intractable seizures and developmental impairment or regression.<sup><xref rid="awac081-B11" ref-type="bibr">11</xref></sup></p>
      <p>Here we report two unrelated patients with biallelic <italic toggle="yes">CACNA2D1</italic> variants, one with a homozygous frameshift variant and the other with compound heterozygosity for an early frameshift and a missense variant. Both individuals show a highly consistent phenotype, corresponding to DEE. We demonstrate that the homozygous frameshift variant causes &#x3B1;<sub>2</sub>&#x3B4;-1 loss in patient fibroblasts, and investigate the effect of the &#x3B1;<sub>2</sub>&#x3B4;-1 amino-acid change p.(Gly209Asp) on calcium channel function. Our data indicate that biallelic loss-of-function variants in <italic toggle="yes">CACNA2D1</italic> underlie this DEE.</p>
    </sec>
    <sec sec-type="materials|methods" id="awac081-s2">
      <title>Materials and methods</title>
      <sec id="awac081-s2.1">
        <title>Patients</title>
        <p>Informed consent for genetic analyses was obtained for the two patients. Genetic studies were performed clinically or as approved by the Institutional Review Boards of the relevant institutions (Ethics Committee, Hamburg Medical Chamber; PV3802). The patients&#x2019; parents provided written informed consent for study participation, clinical data and specimen collection, genetic analysis and publication of relevant findings.</p>
      </sec>
      <sec id="awac081-s2.2">
        <title>Exome sequencing, analysis and variant validation</title>
        <p>Genomic DNA was extracted from peripheral blood samples using standard procedures. We performed trio exome sequencing with DNA samples of Patient 1 and both healthy parents (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>). Primer sequences are in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>. For Patient 2, trio exome sequencing was undertaken with DNA samples of the proband and both healthy parents at Baylor Genetics (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>).</p>
      </sec>
      <sec id="awac081-s2.3">
        <title>RNA isolation and transcript analysis</title>
        <p>RNA isolation from fibroblasts, complementary DNA synthesis, polymerase chain reaction (PCR) and Sanger sequencing of amplicons to analyse <italic toggle="yes">CACNA2D1</italic> transcripts were performed as described.<sup><xref rid="awac081-B12" ref-type="bibr">12</xref></sup> Quantitative PCR to determine the relative mRNA levels of <italic toggle="yes">CACNA2D1</italic> and <italic toggle="yes">CACNA2D3</italic> was performed as described.<sup><xref rid="awac081-B12" ref-type="bibr">12</xref></sup> Primer sequences are in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>.</p>
      </sec>
      <sec id="awac081-s2.4">
        <title>Bioinformatic analysis of CACNA2D1 homologues</title>
        <p>Details of bioinformatic analysis are described in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>.</p>
      </sec>
      <sec id="awac081-s2.5">
        <title>Cell culture and antibodies</title>
        <p>Primary fibroblasts, tsA-201 cells and hippocampal neurons were cultured as described (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>). The antibodies used are described in <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>.</p>
      </sec>
      <sec id="awac081-s2.6">
        <title>Immunoblot analysis of fibroblasts</title>
        <p>Whole-cell lysates from patient and control fibroblasts were prepared, and immunoblotting performed as described<sup><xref rid="awac081-B12" ref-type="bibr">12</xref></sup> (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>).</p>
      </sec>
      <sec id="awac081-s2.7">
        <title>Expression constructs, mutagenesis and cell transfection</title>
        <p>Details of expression constructs, transfection markers and procedures are detailed in <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>. The tsA-201 cells were transfected with PolyJet or Fugene6 (as stated) according to manufacturers&#x2019; protocols. Hippocampal neurons were transfected with Lipofectamine 2000 (Life Technologies).</p>
      </sec>
      <sec id="awac081-s2.8">
        <title>Electrophysiology</title>
        <p>Ca<sub>V</sub>2.1 and Ca<sub>V</sub>2.2 currents in transfected tsA-201 cells were investigated by whole-cell patch-clamp recording (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>).</p>
      </sec>
      <sec id="awac081-s2.9">
        <title>Cell surface biotinylation, co-immunoprecipitation and immunocytochemistry</title>
        <p>Cell surface biotinylation, co-immunoprecipitation, immunoblotting and immunocytochemistry was performed as described in Kadurin <italic toggle="yes">et al</italic>.<sup><xref rid="awac081-B13" ref-type="bibr">13</xref></sup> (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>).</p>
      </sec>
      <sec id="awac081-s2.10">
        <title>Data analysis and availability</title>
        <p>Data analysis and availability are described in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="awac081-s3">
      <title>Results</title>
      <sec id="awac081-s3.1">
        <title>Biallelic variants in <italic toggle="yes">CACNA2D1</italic> in two unrelated individuals with DEE</title>
        <p>Through GeneMatcher,<sup><xref rid="awac081-B14" ref-type="bibr">14</xref></sup> we identified the two unrelated male individuals, Patients 1 and 2, with a highly consistent phenotype corresponding to DEE. The two affected individuals carried biallelic pathogenic variants in <italic toggle="yes">CACNA2D1</italic> (<xref rid="awac081-T1" ref-type="table">Tables 1</xref> and <xref rid="awac081-T2" ref-type="table">2</xref>). Patient 1 developed generalized seizures at age 19 months, while onset of epilepsy was at age 11.5 months in Patient 2. At last examination, Patient 1 was 4 years 11 months and Patient 2 was 4 years old. Both were microcephalic, had severe hypotonia, absent speech, spasticity, choreiform movements, orofacial dyskinesia and cortical visual impairment (<xref rid="awac081-T1" ref-type="table">Tables 1</xref> and <xref rid="awac081-T2" ref-type="table">2</xref>, and case reports in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>). Brain imaging revealed corpus callosum hypoplasia and progressive volume loss in both (<xref rid="awac081-F1" ref-type="fig">Fig. 1A and B</xref>). Patient 1 had no cardiac anomalies, while a tiny patent foramen ovale was found in Patient 2 (<xref rid="awac081-T1" ref-type="table">Tables 1</xref> and <xref rid="awac081-T2" ref-type="table">2</xref>).</p>
        <fig position="float" id="awac081-F1" fig-type="figure">
          <label>Figure 1</label>
          <caption>
            <p>
<bold>MRI scans of patients with biallelic variants in <italic toggle="yes">CACNA2D1</italic> and determination of <italic toggle="yes">CACNA2D1</italic> mRNA and &#x3B1;<sub>2</sub>&#x3B4;-1 protein levels in patient-derived fibroblasts.</bold> (<bold>A</bold>) In Patient 1, T<sub>2</sub>-weighted sagittal MRI shows hypoplastic corpus callosum and T<sub>1</sub>-weighted axial image shows enlarged ventricles and frontotemporal CSF spaces at the age of 7 months. At the age of 4 years and 10 months, progressive frontotemporal and mesial temporal atrophy was noted. (<bold>B</bold>) At the age of 11 months, T<sub>1</sub>-weighted sagittal and T<sub>2</sub>-weighted axial MRI images of Patient 2 show non-specific findings of delayed myelination within the frontal and parietal white matter for age and prominent perivascular spaces. At the age of 26 months, T<sub>1</sub>-weighted sagittal MRI shows interval generalized volume loss with extra-axial spaces and thinning of the corpus callosum. T<sub>2</sub>-weighted axial images show an increase in ventricular size in addition to increased intra-axial spaces. Permission to publish MRI scans was provided for the two patients shown here. (<bold>C</bold>) Relative quantification of <italic toggle="yes">CACNA2D1</italic> transcripts by reverse transcription-qPCR (RT-qPCR) using two <italic toggle="yes">CACNA2D1</italic>-specific primer pairs generating amplicons for exons 6&#x2013;7 and 10&#x2013;11. RNA was obtained from fibroblasts of Patients 1 and 2 and three healthy individuals (Controls 1&#x2013;3). Glyceraldehyde-3-phosphate dehydrogenase (<italic toggle="yes">GAPDH</italic>) mRNA was used as an internal control; and the amount of target mRNA relative to <italic toggle="yes">GAPDH</italic> mRNA is presented. Mean&#x2009;&#xB1;&#x2009; standard error of the mean (SEM) of three independent experiments, each performed in triplicate, is shown. One-way ANOVA with Bonferroni <italic toggle="yes">post hoc</italic> test for multiple comparisons was used for statistical analysis: ns, <italic toggle="yes">P</italic>&#x2009;&gt;&#x2009;0.05; ***<italic toggle="yes">P</italic>&#x2009;=&#x2009;0.0001; ****<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0001. Datasets of independent RT-qPCR experiments with technical triplicates are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 2</xref>. (<bold>D</bold>) Representative immunoblot of whole-cell lysates obtained from fibroblasts of Patients 1 and 2 and three controls. The amount of &#x3B1;<sub>2</sub>&#x3B4;-1 was monitored with an anti-&#x3B1;<sub>2</sub>&#x3B4;-1 antibody. An anti-tubulin antibody was used to demonstrate equal loading. A band corresponding to &#x3B1;<sub>2</sub>&#x3B4;-1, which shows a low expression in fibroblasts, was observed in all control cells. Uncropped blots are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 3</xref>. (<bold>E</bold>) Band intensities were quantified using the ChemiDoc imaging system. Mean&#x2009;&#xB1;&#x2009;SEM with individual data-points of three independent experiments is shown. One-way ANOVA followed by a Bonferroni <italic toggle="yes">post hoc</italic> test for multiple comparisons was used for statistical analysis: **<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0065; ***<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0005; ****<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0001. Ctrl = control; ex = exon; ns = not significant; P = patient.</p>
          </caption>
          <graphic xlink:href="awac081f1" position="float"/>
        </fig>
        <table-wrap position="float" id="awac081-T1">
          <label>Table 1</label>
          <caption>
            <p>
Family history, growth parameters and manifestation of first symptoms in patients with biallelic <italic toggle="yes">CACNA2D1</italic> variants
</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="center" span="1"/>
              <col valign="top" align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="center" rowspan="1" colspan="1">Patient 1</th>
                <th align="center" rowspan="1" colspan="1">Patient 2</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Ethnicity</td>
                <td rowspan="1" colspan="1">Afghan</td>
                <td rowspan="1" colspan="1">Caucasian, Native American</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Parental consanguinity</td>
                <td rowspan="1" colspan="1">First cousins</td>
                <td rowspan="1" colspan="1">No</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Family history</td>
                <td rowspan="1" colspan="1">Epileptic encephalopathy in paternal uncle</td>
                <td rowspan="1" colspan="1">No</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sex</td>
                <td rowspan="1" colspan="1">Male</td>
                <td rowspan="1" colspan="1">Male</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<italic toggle="yes">CACNA2D1</italic> variants (NM_000722.3)</td>
                <td rowspan="1" colspan="1">c.818_821dup/p.(Ser275Asnfs*13) homozygous</td>
                <td rowspan="1" colspan="1">c.13_23dup/p.(Leu9Alafs*5) and c.626G&gt;A/p.(Gly209Asp) compound heterozygous</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Pregnancy</td>
                <td rowspan="1" colspan="1">Uncomplicated</td>
                <td rowspan="1" colspan="1">Uncomplicated</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Birth at</td>
                <td rowspan="1" colspan="1">37 weeks, uncomplicated</td>
                <td rowspan="1" colspan="1">40 weeks</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Birth weight, g/<italic toggle="yes">z</italic>-score</td>
                <td rowspan="1" colspan="1">2960/&#x2212;0.5</td>
                <td rowspan="1" colspan="1">3345/&#x2212;0.73</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Birth length, cm/<italic toggle="yes">z</italic>-score</td>
                <td rowspan="1" colspan="1">50/&#x2212;0.2</td>
                <td rowspan="1" colspan="1">Unknown</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">OFC at birth, cm/<italic toggle="yes">z</italic>-score</td>
                <td rowspan="1" colspan="1">33/&#x2212;1.0</td>
                <td rowspan="1" colspan="1">Unknown</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Age at last examination</td>
                <td rowspan="1" colspan="1">4 years 11 months</td>
                <td rowspan="1" colspan="1">4 years</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Weight at last examination, kg/<italic toggle="yes">z</italic>-score</td>
                <td rowspan="1" colspan="1">18/&#x2212;0.4</td>
                <td rowspan="1" colspan="1">15.5/&#x2212;0.52</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Length at last examination, cm/<italic toggle="yes">z</italic>-score</td>
                <td rowspan="1" colspan="1">110/&#x2212;0.2</td>
                <td rowspan="1" colspan="1">97.8/&#x2212;0.68</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">OFC at last examination, cm/<italic toggle="yes">z</italic>-score</td>
                <td rowspan="1" colspan="1">48.9/&#x2212;2.1</td>
                <td rowspan="1" colspan="1">47.5/&#x2212;2.02</td>
              </tr>
              <tr>
                <td colspan="3" rowspan="1">
<bold>Manifestation</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">First symptoms at age of</td>
                <td rowspan="1" colspan="1">3 months</td>
                <td rowspan="1" colspan="1">&lt;2 months</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">First clinical signs</td>
                <td rowspan="1" colspan="1">Severe hypotonia with poor head control, no visual attention</td>
                <td rowspan="1" colspan="1">Hypotonia with poor head control, decreased visual attention</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap position="float" id="awac081-T2">
          <label>Table 2</label>
          <caption>
            <p>
Neurological and other findings in patients with biallelic <italic toggle="yes">CACNA2D1</italic> variants
</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
              <col valign="top" align="left" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" colspan="3" rowspan="1">Neurological signs</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Global developmental delay</td>
                <td rowspan="1" colspan="1">Profound</td>
                <td rowspan="1" colspan="1">Profound</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Motor skills</td>
                <td rowspan="1" colspan="1">No achievement of motor milestones</td>
                <td rowspan="1" colspan="1">Rolls to one side, reaches for toys intermittently</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Muscular hypotonia</td>
                <td rowspan="1" colspan="1">Severe axial, insufficient head control</td>
                <td rowspan="1" colspan="1">Markedly low axial tone, appendicular tone is also low, increased with activation</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Spasticity</td>
                <td rowspan="1" colspan="1">In all extremities, starting at 2 years</td>
                <td rowspan="1" colspan="1">Hands often fisted since birth, spastic catch at elbows and knees more prominent over time, back arching episodes beginning&#x2009;&lt;12 months</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Dystonic movements</td>
                <td rowspan="1" colspan="1">Choreiform movements of upper extremities, orofacial dyskinesia, onset&#x2009;&lt;2 years</td>
                <td rowspan="1" colspan="1">Distal choreiform movements of all extremities, orofacial dyskinesia and generalized dystonic episodes, onset&#x2009;&lt;10 months</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Intellectual disability</td>
                <td rowspan="1" colspan="1">Profound</td>
                <td rowspan="1" colspan="1">Profound</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Speech impairment</td>
                <td rowspan="1" colspan="1">Profound</td>
                <td rowspan="1" colspan="1">Profound</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Behaviour</td>
                <td rowspan="1" colspan="1">No concerns</td>
                <td rowspan="1" colspan="1">No concerns</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cerebral MRI</td>
                <td rowspan="1" colspan="1">Hypoplastic corpus callosum, enlarged inner and outer CSF spaces at age 7 months; progressive frontotemporal and mesial temporal atrophy at 4 years 10 months</td>
                <td rowspan="1" colspan="1">Generalized volume loss, borderline thinning of the corpus callosum at 11 months; progression of generalized volume loss at 26 months</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hearing</td>
                <td rowspan="1" colspan="1">Normal, not tested</td>
                <td rowspan="1" colspan="1">Normal</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Eyes</td>
                <td rowspan="1" colspan="1">Cortical visual impairment, nystagmus</td>
                <td rowspan="1" colspan="1">Cortical visual impairment, intermittent disconjugate gaze</td>
              </tr>
              <tr>
                <td colspan="3" rowspan="1">
<bold>Seizures</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Age of onset</td>
                <td rowspan="1" colspan="1">9 months: absences; 19&#x2005;months: generalized seizures</td>
                <td rowspan="1" colspan="1">11 months: right face/arm twitching, abnormal EEG</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Initial seizure type</td>
                <td rowspan="1" colspan="1">Absences, generalized</td>
                <td rowspan="1" colspan="1">Focal with impaired awareness (hemi-clonic), atypical absence</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Current seizure type</td>
                <td rowspan="1" colspan="1">Absences</td>
                <td rowspan="1" colspan="1">Focal with impaired awareness (hemi-clonic), 3 years 9 months: ESES</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Response to treatment</td>
                <td rowspan="1" colspan="1">Well (generalized seizures), poor (absences)</td>
                <td rowspan="1" colspan="1">Well controlled on Depakene</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">EEG</td>
                <td rowspan="1" colspan="1">Normal at age 7 months</td>
                <td rowspan="1" colspan="1">11 months: diffusely slow, no anterior posterior frequency amplitude gradient, slow spike and wave in sleep, multifocal spikes. Focal motor seizure captured, some irregular generalized spikes with possible eye blinking and unresponsive.<break/>3 years 9 months: mild diffuse slowing, occasional multifocal sharps and 2&#x2013;3&#x2005;Hz spike and wave during wakefulness, near continuous slow spike and wave during sleep meeting criteria for ESES</td>
              </tr>
              <tr>
                <td colspan="3" rowspan="1">
<bold>Feeding</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Feeding difficulties</td>
                <td rowspan="1" colspan="1">G tube placement at 4 years</td>
                <td rowspan="1" colspan="1">Since birth, s/p G tube placement at 13 months</td>
              </tr>
              <tr>
                <td colspan="3" rowspan="1">
<bold>Cardiac features</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Echocardiography</td>
                <td rowspan="1" colspan="1">Normal</td>
                <td rowspan="1" colspan="1">Limited study with tiny patent foramen ovale, normal function</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Electrocardiography</td>
                <td rowspan="1" colspan="1">Normal</td>
                <td rowspan="1" colspan="1">Normal, including 24&#x2005;h patch recording</td>
              </tr>
              <tr>
                <td colspan="3" rowspan="1">
<bold>Other findings</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Facial dysmorphism</td>
                <td rowspan="1" colspan="1">Bitemporal narrowing, large ears, flared medial eyebrows, open mouth with tented upper lip</td>
                <td rowspan="1" colspan="1">Microcephalic with posterior plagiocephaly, mild bitemporal narrowing, ears are low set and appear larger relative to head size, mild ptosis bilaterally, mouth held hanging open, high arched palate, teeth are widely spaced and blunted due to frequent bruxism, small hands and feet</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sleep disturbance</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Obstructive sleep apnoea</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Insensibility to pain</td>
                <td rowspan="1" colspan="1">Yes</td>
                <td rowspan="1" colspan="1">Yes</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="awac081-tblfn2">
              <p>ESES = electrical status epilepticus in sleep; s/p = status post.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Trio exome sequencing in Patient 1 and parents revealed in the proband the homozygous <italic toggle="yes">CACNA2D1</italic> (NM_000722.3) frameshift variant c.818_821dupGAAC/p.(Ser275Asnfs*13). The variant is absent from public databases including gnomAD (v.2.1.1 and 3.1.1). The 4-bp duplication was validated in Patient 1&#x2019;s DNA and fibroblast-derived complementary DNA. His healthy parents were heterozygous carriers (<xref rid="awac081-T1" ref-type="table">Tables 1</xref> and <xref rid="awac081-T2" ref-type="table">2</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>). In Patient 2, trio exome sequencing demonstrated compound heterozygosity for the <italic toggle="yes">CACNA2D1</italic> variants c.13_23dupTGCCTGCTGGC [p.(Leu9Alafs*5)] and c.626G&gt;A [p.(Gly209Asp)] (<xref rid="awac081-T1" ref-type="table">Tables 1</xref> and <xref rid="awac081-T2" ref-type="table">2</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>). His healthy mother was heterozygous for the c.13_23dupTGCCTGCTGGC variant and his healthy father for the c.626G&gt;A variant. The 11-bp duplication is probably a loss-of-function variant; it has a worldwide minor allele frequency of 0.003% (gnomAD v.2.1.1), while the c.626G&gt;A variant is absent in gnomAD (v.2.1.1 and 3.1.1). The missense variant c.626G&gt;A/p.(Gly209Asp) in exon 7 is predicted to be damaging by <italic toggle="yes">in silico</italic> tools detailed in the <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>.</p>
        <p>In fibroblasts of Patient 1, <italic toggle="yes">CACNA2D1</italic> mRNA level was reduced to 6&#x2013;9% compared with control fibroblasts, while it was similar in Patient 2 and control fibroblasts (<xref rid="awac081-F1" ref-type="fig">Fig. 1C</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 2</xref>). We next determined &#x3B1;<sub>2</sub>&#x3B4;-1 levels in whole-cell lysates from cultured primary fibroblasts of Patients 1 and 2. Qualitatively, we detected little full-length &#x3B1;<sub>2</sub>&#x3B4;-1 in Patient 1 fibroblasts, while it was present in Patient 2 and control cells (<xref rid="awac081-F1" ref-type="fig">Fig. 1D</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 3</xref>). Quantification of &#x3B1;<sub>2</sub>&#x3B4;-1 indicated 10&#x2013;12% in Patient 1 and 31&#x2013;38% in Patient 2 compared to controls (<xref rid="awac081-F1" ref-type="fig">Fig. 1E</xref>). Together, these data indicate that Patient 1 carries biallelic <italic toggle="yes">CACNA2D1</italic> loss-of-function alleles and Patient 2 harbours at least one <italic toggle="yes">CACNA2D1</italic> loss-of-function variant.</p>
        <p>Next, we investigated mRNA levels of the other <italic toggle="yes">CACNA2D</italic> genes in patient fibroblasts to identify possible compensatory effects. While mRNA levels of <italic toggle="yes">CACNA2D2</italic> and <italic toggle="yes">CACNA2D4</italic> were too low to be quantified, we detected 3- to 7-fold higher <italic toggle="yes">CACNA2D3</italic> mRNA levels in Patient 2 fibroblasts compared to Patient 1 and control cells (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 4</xref>).</p>
      </sec>
      <sec id="awac081-s3.2">
        <title>Glycine 209 is invariant in CACNA2D1</title>
        <p>The &#x3B1;<sub>2</sub>&#x3B4;-1 protein (also denoted as CACNA2D1) contains a von Willebrand factor-A domain and four Ca<sup>2+</sup> channel and chemotaxis receptor (Cache) domains,<sup><xref rid="awac081-B15" ref-type="bibr">15</xref></sup> organized into two double-Cache (dCache) domains.<sup><xref rid="awac081-B16" ref-type="bibr">16</xref></sup> The p.(Gly209Asp) (G209D) amino-acid substitution in the CACNA2D1 gene product of Patient 2 is within the gabapentin and amino-acid binding pocket of its dCache_1 domain.<sup><xref rid="awac081-B16" ref-type="bibr">16</xref></sup> This Gly residue is important for maintaining a three-strand beta-sheet stability and simultaneously providing a critical turn in the structure. G209 is absolutely invariant in both CACNA2D1 and CACNA2D2 orthologues in all vertebrates and paralogues and predecessors from low invertebrates (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 5</xref>).</p>
      </sec>
      <sec id="awac081-s3.3">
        <title>The p.(Gly209Asp) variant disrupts plasma membrane &#x3B1;<sub>2</sub>&#x3B4;-1 expression</title>
        <p>We then investigated the <italic toggle="yes">in vitro</italic> effect of the p.(Gly209Asp) variant on &#x3B1;<sub>2</sub>&#x3B4;-1 as a calcium channel subunit. First, we compared cell surface expression of wild-type HA-&#x3B1;<sub>2</sub>&#x3B4;-1 (HA-&#x3B1;2&#x3B4;-1 WT) and HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G20n9D</sup> in non-permeabilized cells.<sup><xref rid="awac081-B5" ref-type="bibr">5</xref></sup> As shown by the haemagglutinin (HA) signal, the expression of HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> at the cell surface was reduced by &#x223C;80% compared to HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (<xref rid="awac081-F2" ref-type="fig">Fig. 2A and B</xref>). In agreement, cell surface biotinylated HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> was decreased, by 86.2%, compared to HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (<xref rid="awac081-F2" ref-type="fig">Fig. 2C and D</xref>).</p>
        <fig position="float" id="awac081-F2" fig-type="figure">
          <label>Figure 2</label>
          <caption>
            <p>
<bold>The p.(Gly209Asp) variant disrupts &#x3B1;<sub>2</sub>&#x3B4;-1 expression at the cell surface</bold>, <bold>and does not promote Ca<sub>V</sub>2 calcium currents.</bold> (<bold>A</bold>) Representative confocal images of tsA-201 cells transfected with either HA-&#x3B1;<sub>2</sub>&#x3B4;-1 wild-type (WT) or HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> with mCherry. HA staining was performed in non-permeabilized conditions and shown in the <italic toggle="yes">left</italic> panels. The <italic toggle="yes">right</italic> panels represent the merged images with the 10&#x2005;&#x3BC;m scale bar. (<bold>B</bold>) Bar charts (mean&#x2009;&#xB1;&#x2009;SEM with individual data-points, each representing mean of at least 60 cells) showing the expression at the cell surface (HA signal) of WT &#x3B1;<sub>2</sub>&#x3B4;-1-HA (blue bar) and HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (green bar). Data obtained from six coverslips in two independent experiments, ****<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0001, Student&#x2019;s <italic toggle="yes">t</italic>-test. (<bold>C</bold>) Western blot experiments for HA-&#x3B1;<sub>2</sub>&#x3B4;-1 (anti-HA Ab, <italic toggle="yes">top</italic>; molecular weight &#x223C;140&#x2013;170&#x2005;kDa for the glycosylated uncleaved and proteolytically cleaved &#x3B1;<sub>2</sub>&#x3B4;-1 proteins) and GAPDH (used as a control, <italic toggle="yes">bottom</italic>). <italic toggle="yes">Left</italic> panels show whole-cell lysate (WCL) input and <italic toggle="yes">right</italic> panels show cell surface biotinylated samples from tsA-201 cells transfected with HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (lane 1) or HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (lane 2) or empty vector (EV, lane 3). Western blots were performed under reducing conditions, such that the disulphide bonds between &#x3B1;2 and &#x3B4; were broken. Uncropped blots are in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 10A</xref>. (<bold>D</bold>) Mean&#x2009;&#xB1;&#x2009;SEM and individual data-points of cell surface HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (blue bar) or HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (green bar) measured as a proportion of biotinylated over total protein normalized to HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT. **<italic toggle="yes">P</italic>&#x2009;=&#x2009;0.0012, Student&#x2019;s <italic toggle="yes">t</italic>-test. (<bold>E</bold>) Example of whole-cell patch-clamp recordings for Ca<sub>V</sub>2.2-HA co-expressed with &#x3B2;1b and either &#x3B1;<sub>2</sub>&#x3B4;-1 WT (blue, <italic toggle="yes">left</italic>), empty vector (no &#x3B1;<sub>2</sub>&#x3B4;, red, centre) or &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (green, <italic toggle="yes">right</italic>). Holding potential &#x2212;80&#x2005;mV, steps between &#x2212;50 and +60&#x2005;mV for 50&#x2005;ms (applies to all traces). (<bold>F</bold>) Mean (&#xB1; SEM) <italic toggle="yes">IV</italic> relationships for the conditions shown in <bold>E</bold>. Ca<sub>V</sub>2.2-HA co-expressed with &#x3B1;<sub>2</sub>&#x3B4;-1 WT (<italic toggle="yes">n</italic>&#x2009;=&#x2009;14, blue fileld circles), empty vector (no &#x3B1;<sub>2</sub>&#x3B4;, <italic toggle="yes">n</italic>&#x2009;=&#x2009;10, red filled circles) or &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<italic toggle="yes">n</italic>&#x2009;=&#x2009;10, green filled circles). The individual and mean data were fit with a modified Boltzmann equation (see &#x2018;Materials and methods&#x2019; section). (<bold>G</bold>) G<sub>max</sub> [nanosiemens (nS)/picofarad (pF)] from the <italic toggle="yes">IV</italic> relationships shown in <bold>F</bold>. Individual data (same symbols as in <bold>F</bold>) and mean&#x2009;&#xB1;&#x2009;SEM are plotted. ****<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0001 versus wild-type (one-way ANOVA and Sidak&#x2019;s <italic toggle="yes">post hoc</italic> test correcting for multiple comparisons).</p>
          </caption>
          <graphic xlink:href="awac081f2" position="float"/>
        </fig>
      </sec>
      <sec id="awac081-s3.4">
        <title>The p.(Gly209Asp) variant abolishes ability of &#x3B1;<sub>2</sub>&#x3B4;-1 to promote Ca<sub>V</sub>2.2 currents</title>
        <p>Ca<sub>V</sub>2.2 currents were then measured in tsA-201 cells transfected with HA-tagged Ca<sub>V</sub>2.2 with &#x3B2;1b and &#x3B1;<sub>2</sub>&#x3B4;-1 wild-type, &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> or no &#x3B1;<sub>2</sub>&#x3B4;. While &#x3B1;<sub>2</sub>&#x3B4;-1 wild-type increased Ca<sub>V</sub>2.2 currents by &#x223C;13-fold, &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> produced no increase compared to without &#x3B1;<sub>2</sub>&#x3B4; (<xref rid="awac081-F2" ref-type="fig">Fig. 2E&#x2013;G</xref>). Expression of all subunits was confirmed by western blotting and immunocytochemistry (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 6</xref>). This effect was not specific to Ca<sub>V</sub>2.2, as &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> also did not increase Ca<sub>V</sub>2.1 currents (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 7A&#x2013;C</xref>).</p>
        <p>We next investigated expression of the calcium channel complex at the plasma membrane, using double-tagged GFP_Ca<sub>V</sub>2.2-HA. When GFP_Ca<sub>V</sub>2.2-HA was co-expressed with &#x3B1;<sub>2</sub>&#x3B4;-1 wild-type, this resulted in an increase in its cell surface expression compared with no &#x3B1;<sub>2</sub>&#x3B4; control (<xref rid="awac081-F3" ref-type="fig">Fig. 3A and B</xref>). However, this effect was completely absent when Ca<sub>V</sub>2.2 was co-expressed with &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<xref rid="awac081-F3" ref-type="fig">Fig. 3A and B</xref>).</p>
        <fig position="float" id="awac081-F3" fig-type="figure">
          <label>Figure 3</label>
          <caption>
            <p>
<bold>&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> does not enhance Ca<sub>V</sub>2.2 expression at the cell surface in tsA-201 cells and hippocampal neurons</bold>. (<bold>A</bold>) Representative confocal images of tsA-201 cells transfected with GFP_Ca<sub>V</sub>2.2-HA with either &#x3B1;<sub>2</sub>&#x3B4;-1 wild-type (WT) (without tag; <italic toggle="yes">top row</italic>), empty vector (no &#x3B1;<sub>2</sub>&#x3B4;, <italic toggle="yes">middle row</italic>) or &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (without tag; <italic toggle="yes">bottom row</italic>). HA staining was performed in non-permeabilized conditions (white, <italic toggle="yes">left</italic>), GFP signal shows total Ca<sub>V</sub>2.2 (<italic toggle="yes">middle</italic>). The right panels represent the merged images (HA is shown in red). Scale bar = 20&#x2005;&#x3BC;m. (<bold>B</bold>) Bar charts (mean&#x2009;&#xB1;&#x2009;SEM with individual data-points representing the mean of at least 50 cells from 12 coverslips) show Ca<sub>V</sub>2.2 expressed at the cell surface (HA signal, grey bars) or total Ca<sub>V</sub>2.2 (GFP, green bars) in the presence of &#x3B1;<sub>2</sub>&#x3B4;-1 WT, empty vector (no &#x3B1;<sub>2</sub>&#x3B4;-1) or &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup>. Data obtained from four independent experiments; ns, <italic toggle="yes">P</italic>&#x2009;&gt;&#x2009;0.05; ***<italic toggle="yes">P</italic>&#x2009;=&#x2009;0.0007, ****<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0001, one-way ANOVA and Bonferroni <italic toggle="yes">post hoc</italic> test. (<bold>C</bold>) Representative confocal images of hippocampal somata imaged at &#xD7;63 objective and transfected with GFP_Ca<sub>V</sub>2.2-HA and either &#x3B1;<sub>2</sub>&#x3B4;-1 WT (<italic toggle="yes">top row</italic>), empty vector (no &#x3B1;<sub>2</sub>&#x3B4;, <italic toggle="yes">middle row</italic>) or &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<italic toggle="yes">bottom row</italic>) together with &#x3B2;1b and mCherry. HA staining was performed in non-permeabilized conditions (grey, <italic toggle="yes">left</italic>), GFP signal (<italic toggle="yes">middle</italic>) and mCherry (transfection marker, <italic toggle="yes">right</italic>). Scale bar = 10&#x2005;&#x3BC;m. (<bold>D</bold>) Bar charts (mean&#x2009;&#xB1;&#x2009;SEM with individual data-points) of HA (grey bars) and GFP (green bars) for &#x3B1;<sub>2</sub>&#x3B4;-1 WT (<italic toggle="yes">n</italic>&#x2009;=&#x2009;102), no &#x3B1;<sub>2</sub>&#x3B4; (<italic toggle="yes">n</italic>&#x2009;=&#x2009;63) and &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<italic toggle="yes">n</italic>&#x2009;=&#x2009;82). Data obtained from three independent experiments; the values are normalized to &#x3B1;<sub>2</sub>&#x3B4;-1 WT condition in each experiment. ns, <italic toggle="yes">P</italic>&#x2009;&gt;&#x2009;0.05; ****<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0001, one-way ANOVA and Bonferroni <italic toggle="yes">post hoc</italic> test. (<bold>E</bold>) Representative confocal images of hippocampal neurons imaged at &#xD7;20 objective and transfected with GFP_Ca<sub>V</sub>2.2-HA and either &#x3B1;<sub>2</sub>&#x3B4;-1 WT (<italic toggle="yes">top row</italic>), empty vector (no &#x3B1;<sub>2</sub>&#x3B4;, <italic toggle="yes">middle row</italic>) or &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<italic toggle="yes">bottom row</italic>) together with &#x3B2;1b and mCherry. HA staining was performed in non-permeabilized conditions (grey, <italic toggle="yes">left</italic> panels), GFP signal (<italic toggle="yes">middle</italic>) and mCherry (transfection marker, <italic toggle="yes">right</italic>). Scale bar = 50 &#x3BC;m. (<bold>F</bold>) Bar charts (mean&#x2009;&#xB1;&#x2009;SEM with individual data-points) of HA (grey bars) and GFP (green bars) for &#x3B1;<sub>2</sub>&#x3B4;-1 WT (<italic toggle="yes">n</italic>&#x2009;=&#x2009;114), no &#x3B1;<sub>2</sub>&#x3B4; (<italic toggle="yes">n</italic>&#x2009;=&#x2009;50) and &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<italic toggle="yes">n</italic>&#x2009;=&#x2009;117). Data obtained from three independent experiments; the values are normalized to &#x3B1;<sub>2</sub>&#x3B4;-1 WT condition in each experiment. ns, <italic toggle="yes">P</italic>&#x2009;&gt;&#x2009;0.05; ****<italic toggle="yes">P</italic>&#x2009;&lt;&#x2009;0.0001, one-way ANOVA and Bonferroni <italic toggle="yes">post hoc</italic> test. Note that for <bold>B</bold>, <bold>D</bold> and <bold>F</bold>, total Ca<sub>V</sub>2.2 (GFP) was reduced in both the &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> and no &#x3B1;<sub>2</sub>&#x3B4; conditions compared to &#x3B1;<sub>2</sub>&#x3B4;-1 WT condition probably because of its increased degradation when Ca<sub>V</sub>2.2 is poorly trafficked out of the endoplasmic reticulum.</p>
          </caption>
          <graphic xlink:href="awac081f3" position="float"/>
        </fig>
      </sec>
      <sec id="awac081-s3.5">
        <title>&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> does not promote Ca<sub>V</sub>2.2 cell surface expression or trafficking in hippocampal neurons</title>
        <p>Ca<sub>V</sub>2.2 is a neuronal calcium channel, and we therefore investigated the effect of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> on Ca<sub>V</sub>2.2 trafficking in neurons, as previously described.<sup><xref rid="awac081-B13" ref-type="bibr">13</xref></sup> We first analysed cell surface expression of GFP_Ca<sub>V</sub>2.2-HA in cultured hippocampal cell bodies. As expected, in the presence of &#x3B1;<sub>2</sub>&#x3B4;-1 WT, GFP_Ca<sub>V</sub>2.2-HA was strongly expressed at the cell surface (HA signal, <xref rid="awac081-F3" ref-type="fig">Fig. 3C and D</xref>). In contrast, in the presence of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup>, GFP_Ca<sub>V</sub>2.2-HA could not be detected at the cell surface, similar to no &#x3B1;<sub>2</sub>&#x3B4; (<xref rid="awac081-F3" ref-type="fig">Fig. 3C and D</xref>).</p>
        <p>The neurites of these cells were then imaged. As expected, GFP_Ca<sub>V</sub>2.2-HA showed strong expression when co-expressed with &#x3B1;<sub>2</sub>&#x3B4;-1 WT; this was observed for both HA (cell surface) and green fluorescent protein (GFP) (total Ca<sub>V</sub>2.2) (<xref rid="awac081-F3" ref-type="fig">Fig. 3E and F</xref>). In contrast, &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> did not promote trafficking of Ca<sub>V</sub>2.2 into hippocampal neurites (<xref rid="awac081-F3" ref-type="fig">Fig. 3E and F</xref>). This is indicated by the finding that both HA (cell surface Ca<sub>V</sub>2.2) and GFP (total Ca<sub>V</sub>2.2) signals were reduced in parallel.</p>
      </sec>
      <sec id="awac081-s3.6">
        <title>&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> shows reduced complex formation with Ca<sub>V</sub>2.2 and limited proteolytic cleavage</title>
        <p>To examine whether the lack of ability of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> to promote calcium channel function was due to reduced interaction with Ca<sub>V</sub>2.2, we performed co-immunoprecipitation experiments, using GFP_Ca<sub>V</sub>2.2-HA (<xref rid="awac081-F4" ref-type="fig">Fig. 4A</xref>). For &#x3B1;<sub>2</sub>&#x3B4;-1 WT, robust interaction was shown by the presence of HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT, co-immunoprecipitated by GFP_Ca<sub>V</sub>2.2-HA, using anti-GFP antibody (<xref rid="awac081-F4" ref-type="fig">Fig. 4A</xref>, lane 6). In contrast, very weak co-immunoprecipitation was observed for HA-&#x3B1;2&#x3B4;-1<sup>G209D</sup> (<xref rid="awac081-F4" ref-type="fig">Fig. 4A</xref>, lane 7), quantified in <xref rid="awac081-F4" ref-type="fig">Fig. 4B</xref>. As a control, there was no co-immunoprecipitation of HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT using Ca<sub>V</sub>2.2-HA without a GFP tag (<xref rid="awac081-F4" ref-type="fig">Fig. 4A</xref>, lane 5).</p>
        <fig position="float" id="awac081-F4" fig-type="figure">
          <label>Figure 4</label>
          <caption>
            <p>
<bold>&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> shows reduced interaction with Ca<sub>V</sub>2.2</bold>. (<bold>A</bold>) GFP_Ca<sub>V</sub>2.2-HA was co-expressed with &#x3B2;1b and either HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT or HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup>. Both Ca<sub>V</sub>2.2 and &#x3B1;<sub>2</sub>&#x3B4;-1 proteins were detected in the same western blot using anti-HA antibodies. Immunoblots of whole-cell lysates (WCL) input (<italic toggle="yes">left</italic>) and immunoprecipitated (IP using GFP antibodies) samples (<italic toggle="yes">right</italic>) from tsA-201 cells transfected with Ca<sub>V</sub>2.2-HA, &#x3B2;1b and HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (lanes 1 and 5) or GFP-Ca<sub>V</sub>2.2-HA with either HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (lanes 2 and 6) or HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (lanes 3 and 7). Immunoblots with anti-HA antibody reveal Ca<sub>V</sub>2.2-HA and GFP_Ca<sub>V</sub>2.2-HA (<italic toggle="yes">top</italic> bands) and HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT and HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<italic toggle="yes">lower</italic> bands). Immunoprecipitation was performed with anti-GFP antibody to pull down GFP-Ca<sub>V</sub>2.2-HA and the co-immunoprecipitated &#x3B1;<sub>2</sub>&#x3B4;-1 is shown below this on the same blot. Ca<sub>V</sub>2.2-HA lacking GFP tag, used as a negative control, shows a lack of co-immunoprecipitation (co-IP) with HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (lane 5). Arrow (lane 7) indicates increased molecular weight of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> relative to &#x3B1;<sub>2</sub>&#x3B4;-1 WT. Western blots were performed under reducing conditions, such that the disulphide bonds between &#x3B1;<sub>2</sub> and &#x3B4; were broken. Uncropped blots are in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 10B</xref>. (<bold>B</bold>) Mean&#x2009;&#xB1;&#x2009;SEM and individual data-points for co-immunoprecipitation of HA &#x3B1;<sub>2</sub>&#x3B4;-1 WT (blue bar) or &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (green bar) measured as a proportion of total protein (whole-cell lysates) and normalized to HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT. *<italic toggle="yes">P</italic>&#x2009;=&#x2009;0.0281 (ratio paired <italic toggle="yes">t</italic>-test on non-normalized data).</p>
          </caption>
          <graphic xlink:href="awac081f4" position="float"/>
        </fig>
        <p>Interestingly, co-immunoprecipitated HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> (<xref rid="awac081-F4" ref-type="fig">Fig. 4</xref>A, lane 7, arrow) had a noticeably higher apparent molecular weight compared to HA-&#x3B1;<sub>2</sub>&#x3B4;-1 WT (lane 6), and we found this was due to almost complete lack of proteolytic cleavage of HA-&#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> into &#x3B1;<sub>2</sub> and &#x3B4; (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 8</xref>).</p>
        <p>In summary, these results show that &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> remains largely as the uncleaved immature form, indicating that it probably remains in the endoplasmic reticulum. In agreement with our previous results for uncleaved &#x3B1;<sub>2</sub>&#x3B4;-1,<sup><xref rid="awac081-B17" ref-type="bibr">17</xref></sup> it shows much less complex formation with Ca<sub>V</sub>2.2. This result suggested that &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> would be unlikely to interfere with other &#x3B1;<sub>2</sub>&#x3B4; proteins interacting with Ca<sub>V</sub>2.2. In agreement with this, we found that &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> did not affect the ability of &#x3B1;<sub>2</sub>&#x3B4;-3 to enhance Ca<sub>V</sub>2.2 currents (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 9A&#x2013;C</xref>). This result underscores that the p.(Gly209Asp) variant has a loss-of-function effect.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="awac081-s4">
      <title>Discussion</title>
      <p>In the current study, we show that biallelic loss-of-function variants in <italic toggle="yes">CACNA2D1</italic> underlie DEE. In Patient 1 the homozygous frameshift variant p.(Ser275Asnfs*13) causes nonsense-mediated mRNA decay of mutated <italic toggle="yes">CACNA2D1</italic> transcripts and absence of &#x3B1;<sub>2</sub>&#x3B4;-1 in patient-derived fibroblasts. The variants p.(Leu9Alafs*5) and p.(Gly209Asp) in Patient 2 are a combination of a very early frameshift and a missense variant <italic toggle="yes">in trans</italic>, with the latter severely affecting Ca<sub>V</sub>2 calcium channel function.</p>
      <p>Our electrophysiological, biochemical and immunocytochemistry data show that &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> is completely non-functional, in that, unlike wild-type &#x3B1;<sub>2</sub>&#x3B4;-1,<sup><xref rid="awac081-B5" ref-type="bibr">5</xref></sup> it traffics extremely poorly to the cell surface, and does not enhance the function or trafficking of Ca<sub>V</sub>2 channels in both non-neuronal cells and hippocampal neurons. Furthermore, &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> shows markedly reduced cleavage into &#x3B1;<sub>2</sub> and &#x3B4;, an enzymatic process that normally begins in the Golgi apparatus.<sup><xref rid="awac081-B13" ref-type="bibr">13</xref>,<xref rid="awac081-B17" ref-type="bibr">17</xref></sup> This suggests that &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> does not traffic beyond the endoplasmic reticulum. Our previous finding that an uncleavable mutant &#x3B1;<sub>2</sub>&#x3B4;-1 shows lower association with the Ca<sub>V</sub>2.2 &#x3B1;<sub>1</sub> subunit than the mature cleaved &#x3B1;<sub>2</sub>&#x3B4;-1,<sup><xref rid="awac081-B17" ref-type="bibr">17</xref></sup> indicates that the lack of proteolytic cleavage of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> will probably contribute to the observed reduction in interaction of &#x3B1;<sub>2</sub>&#x3B4;-1<sup>G209D</sup> with the Ca<sub>V</sub>2.2 &#x3B1;<sub>1</sub> subunit. This demonstrates the importance of a detailed understanding of &#x3B1;<sub>2</sub>&#x3B4;-1 processing and function, in order to identify the basis for such deleterious variants.</p>
      <p>Variants in <italic toggle="yes">CACNA2D1</italic> have previously been associated with cardiac phenotypes in both humans and mice. Homozygous knockout of <italic toggle="yes">Cacna2d1</italic> in mice resulted in a mild cardiac phenotype and reduced ventricular myocyte calcium current density.<sup><xref rid="awac081-B18" ref-type="bibr">18</xref></sup> These mice also showed peripheral sensory deficits and delayed development of neuropathic pain-related responses.<sup><xref rid="awac081-B19" ref-type="bibr">19</xref></sup> Relevant to this, both patients showed insensibility to pain (<xref rid="awac081-T2" ref-type="table">Table 2</xref>). Transgenic mice constitutively over-expressing &#x3B1;<sub>2</sub>&#x3B4;-1 have no gross nervous system defects.<sup><xref rid="awac081-B20" ref-type="bibr">20</xref></sup> However, they show spontaneous epileptiform EEG abnormalities and behavioural arrest,<sup><xref rid="awac081-B21" ref-type="bibr">21</xref></sup> suggesting that not only the spatial and temporal expression but also the expression strength of &#x3B1;<sub>2</sub>&#x3B4;-1 is critical for proper functioning of the mouse brain. Indeed, &#x3B1;<sub>2</sub>&#x3B4;-1 is the major &#x3B1;<sub>2</sub>&#x3B4; isoform in rodent cerebral cortex.<sup><xref rid="awac081-B22" ref-type="bibr">22</xref></sup> Furthermore, an auto-antibody recognizing &#x3B1;<sub>2</sub>&#x3B4;-1 is found in cases of autoimmune encephalitis<sup><xref rid="awac081-B23" ref-type="bibr">23</xref></sup> and amyotrophic lateral sclerosis associated with type 2 diabetes.<sup><xref rid="awac081-B24" ref-type="bibr">24</xref></sup></p>
      <p>In humans, heterozygous variants in <italic toggle="yes">CACNA2D1</italic> have previously been associated with inherited arrhythmogenic disease, including Brugada<sup><xref rid="awac081-B25" ref-type="bibr">25</xref></sup> and short QT<sup><xref rid="awac081-B26" ref-type="bibr">26</xref></sup> syndromes, as well as infantile spasms<sup><xref rid="awac081-B27" ref-type="bibr">27</xref></sup> and intellectual disability and epilepsy.<sup><xref rid="awac081-B28" ref-type="bibr">28</xref></sup> Re-evaluation of these monoallelic variants, together with genetic data presented here give rise to reasonable doubt about an association of these <italic toggle="yes">CACNA2D1</italic> variants with disease (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>).</p>
      <p>Pathogenic variants in genes encoding several Ca<sub>V</sub> channels have been associated with neurological diseases in humans, ranging from early-onset severe spinocerebellar ataxia with neurodevelopmental deficits to DEE (see <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref>). In <italic toggle="yes">CACNA2D2</italic>, rare biallelic loss-of-function variation has been reported in individuals with DEE, corpus callosum hypoplasia, cerebellar atrophy and ataxia.<sup><xref rid="awac081-B9" ref-type="bibr">9</xref>,<xref rid="awac081-B10" ref-type="bibr">10</xref></sup> The two unrelated patients reported here show considerable clinical overlap with individuals carrying homozygous <italic toggle="yes">CACNA2D2</italic> loss-of-function variants, such as global developmental delay and/or intellectual disability, epilepsy and hypoplasia of the corpus callosum. However, atrophy of the brain affects the cerebrum in the two affected individuals with <italic toggle="yes">CACNA2D1</italic> variants, whereas cerebellar atrophy was consistently reported in subjects with <italic toggle="yes">CACNA2D2</italic> variants.<sup><xref rid="awac081-B29" ref-type="bibr">29</xref></sup> These data indicate that loss of &#x3B1;<sub>2</sub>&#x3B4;-1 or &#x3B1;<sub>2</sub>&#x3B4;-2 cannot be compensated by any of the other &#x3B1;<sub>2</sub>&#x3B4; subunits during development. In agreement with this, important, non-overlapping roles for specific &#x3B1;<sub>2</sub>&#x3B4; proteins in synapse formation <italic toggle="yes">in vitro</italic> have been identified recently, some of which may be calcium channel-independent.<sup><xref rid="awac081-B30" ref-type="bibr">30</xref></sup></p>
      <p>In conclusion, our data demonstrate that biallelic loss-of-function variants in <italic toggle="yes">CACNA2D1</italic> underlie early-onset DEE characterized by microcephaly, profound developmental delay, seizures, visual impairment, truncal hypotonia, limb spasticity and movement disorder. These clinical features are similar to those in previously reported individuals with homozygous <italic toggle="yes">CACNA2D2</italic> null alleles. Individuals with biallelic <italic toggle="yes">CACNA2D1</italic> or <italic toggle="yes">CACNA2D2</italic> variants all have corpus callosum hypoplasia, while patients with <italic toggle="yes">CACNA2D1</italic> variants show progressive cerebral atrophy whereas subjects harbouring <italic toggle="yes">CACNA2D2</italic> variants have cerebellar atrophy. The loss-of-function frameshift nature of two of the three identified <italic toggle="yes">CACNA2D1</italic> variants, together with our functional studies demonstrating a loss-of-function effect for the amino-acid substitution p.(Gly209Asp), confirm disease causation of homozygous and compound heterozygous <italic toggle="yes">CACNA2D1</italic> variants, while also calling into question a causative role of monoallelic <italic toggle="yes">CACNA2D1</italic> variants in intellectual disability, epilepsy and/or inherited arrhythmogenic diseases.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material id="sup1" position="float" content-type="local-data">
        <label>awac081_Supplementary_Data</label>
        <media xlink:href="awac081_supplementary_data.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="ack1">
      <title>Acknowledgements</title>
      <p>We thank the patient families for participation in this study. We further thank Dennis Zorndt and Kanchan Chaggar for skillful technical assistance.</p>
    </ack>
    <sec id="awac081-s5">
      <title>Funding</title>
      <p>This study was supported by grants from Wellcome Trust (grant no. 206279\Z\17\Z to A.C.D.), National Institutes of Health (1R35GM131760 to I.B.Z.) and Deutsche Forschungsgemeinschaft (KU 1240/6-2 and KU 1240/10-1 to K.K.)</p>
    </sec>
    <sec id="awac081-s6">
      <title>Competing interests</title>
      <p>The authors report no competing interests.</p>
    </sec>
    <sec id="awac081-s7">
      <title>Supplementary material</title>
      <p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">Brain</italic> online.</p>
    </sec>
    <ref-list id="ref1">
      <title>References</title>
      <ref id="awac081-B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Catterall</surname>
<given-names>WA</given-names>
</string-name>, <string-name><surname>Lenaeus</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Gamal El-Din</surname><given-names>TM</given-names></string-name></person-group>. <article-title>Structure and pharmacology of voltage-gated sodium and calcium channels</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>2020</year>;<volume>60</volume>:<fpage>133</fpage>&#x2013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">31537174</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>A</given-names></string-name></person-group>. <article-title>Presynaptic calcium channels: Specialized control of synaptic neurotransmitter release</article-title>. <source>Nat Rev Neurosci</source>. <year>2020</year>;<volume>21</volume>:<fpage>213</fpage>&#x2013;<lpage>229</lpage>.<pub-id pub-id-type="pmid">32161339</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>De Jongh</surname>
<given-names>KS</given-names>
</string-name>, <string-name><surname>Warner</surname><given-names>C</given-names></string-name>, <string-name><surname>Catterall</surname><given-names>WA</given-names></string-name></person-group>. <article-title>Subunits of purified calcium channels. &#x3B1;2 and &#x3B4; are encoded by the same gene.</article-title><source>J Biol Chem</source>. <year>1990</year>;<volume>265</volume>:<fpage>14738</fpage>&#x2013;<lpage>14741</lpage>.<pub-id pub-id-type="pmid">2168391</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Davies</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Kadurin</surname><given-names>I</given-names></string-name>, <string-name><surname>Alvarez-Laviada</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>The &#x3B1;2&#x3B4; subunits of voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for function</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2010</year>;<volume>107</volume>:<fpage>1654</fpage>&#x2013;<lpage>1659</lpage>.<pub-id pub-id-type="pmid">20080692</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cassidy</surname>
<given-names>JS</given-names>
</string-name>, <string-name><surname>Ferron</surname><given-names>L</given-names></string-name>, <string-name><surname>Kadurin</surname><given-names>I</given-names></string-name>, <string-name><surname>Pratt</surname><given-names>WS</given-names></string-name>, <string-name><surname>Dolphin</surname><given-names>AC</given-names></string-name></person-group>. <article-title>Functional exofacially tagged N-type calcium channels elucidate the interaction with auxiliary &#x3B1;2&#x3B4;-1 subunits</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2014</year>;<volume>111</volume>:<fpage>8979</fpage>&#x2013;<lpage>8984</lpage>.<pub-id pub-id-type="pmid">24889613</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ablinger</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Geisler</surname><given-names>SM</given-names></string-name>, <string-name><surname>Stanika</surname><given-names>RI</given-names></string-name>, <string-name><surname>Klein</surname><given-names>CT</given-names></string-name>, <string-name><surname>Obermair</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Neuronal &#x3B1;2&#x3B4; proteins and brain disorders</article-title>. <source>Pflugers Arch</source>. <year>2020</year>;<volume>472</volume>:<fpage>845</fpage>&#x2013;<lpage>863</lpage>.<pub-id pub-id-type="pmid">32607809</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B7">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Barclay</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Balaguero</surname><given-names>N</given-names></string-name>, <string-name><surname>Mione</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the <italic toggle="yes">Cacna2d2</italic> gene and decreased calcium channel current in cerebellar Purkinje cells</article-title>. <source>J Neurosci</source>. <year>2001</year>;<volume>21</volume>:<fpage>6095</fpage>&#x2013;<lpage>6104</lpage>.<pub-id pub-id-type="pmid">11487633</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Valence</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Cochet</surname><given-names>E</given-names></string-name>, <string-name><surname>Rougeot</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Exome sequencing in congenital ataxia identifies two new candidate genes and highlights a pathophysiological link between some congenital ataxias and early infantile epileptic encephalopathies</article-title>. <source>Genet Med</source>. <year>2019</year>;<volume>21</volume>:<fpage>553</fpage>&#x2013;<lpage>563</lpage>.<pub-id pub-id-type="pmid">29997391</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B9">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Pippucci</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Parmeggiani</surname><given-names>A</given-names></string-name>, <string-name><surname>Palombo</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>A novel null homozygous mutation confirms <italic toggle="yes">CACNA2D2</italic> as a gene mutated in epileptic encephalopathy</article-title>. <source>PLoS ONE</source>. <year>2013</year>;<volume>8</volume>:<fpage>e82154</fpage>.<pub-id pub-id-type="pmid">24358150</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Edvardson</surname>
<given-names>S</given-names>
</string-name>, <string-name><surname>Oz</surname><given-names>S</given-names></string-name>, <string-name><surname>Abulhijaa</surname><given-names>FA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Early infantile epileptic encephalopathy associated with a high voltage gated calcium channelopathy</article-title>. <source>J Med Genet</source>. <year>2013</year>;<volume>50</volume>:<fpage>118</fpage>&#x2013;<lpage>123</lpage>.<pub-id pub-id-type="pmid">23339110</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</string-name>, <string-name><surname>Berkovic</surname><given-names>S</given-names></string-name>, <string-name><surname>Capovilla</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology</article-title>. <source>Epilepsia</source>. <year>2017</year>;<volume>58</volume>:<fpage>512</fpage>&#x2013;<lpage>521</lpage>.<pub-id pub-id-type="pmid">28276062</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schneeberger</surname>
<given-names>PE</given-names>
</string-name>, <string-name><surname>von Elsner</surname><given-names>L</given-names></string-name>, <string-name><surname>Barker</surname><given-names>EL</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Bi-allelic pathogenic variants in HS2ST1 cause a syndrome characterized by developmental delay and corpus callosum, skeletal, and renal abnormalities</article-title>. <source>Am J Hum Genet</source>. <year>2020</year>;<volume>107</volume>:<fpage>1044</fpage>&#x2013;<lpage>1061</lpage>.<pub-id pub-id-type="pmid">33159882</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Kadurin</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Ferron</surname><given-names>L</given-names></string-name>, <string-name><surname>Rothwell</surname><given-names>SW</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Proteolytic maturation of &#x3B1;2&#x3B4; represents a checkpoint for activation and neuronal trafficking of latent calcium channels</article-title>. <source>eLife</source>. <year>2016</year>;<volume>5</volume>:<fpage>e21143</fpage>.<pub-id pub-id-type="pmid">27782881</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sobreira</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Schiettecatte</surname><given-names>F</given-names></string-name>, <string-name><surname>Valle</surname><given-names>D</given-names></string-name>, <string-name><surname>Hamosh</surname><given-names>A</given-names></string-name></person-group>. <article-title>GeneMatcher: A matching tool for connecting investigators with an interest in the same gene</article-title>. <source>Hum Mutat</source>. <year>2015</year>;<volume>36</volume>:<fpage>928</fpage>&#x2013;<lpage>930</lpage>.<pub-id pub-id-type="pmid">26220891</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Yan</surname><given-names>Z</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Structure of the voltage-gated calcium channel Cav1.1 at 3.6 A resolution</article-title>. <source>Nature</source>. <year>2016</year>;<volume>537</volume>:<fpage>191</fpage>&#x2013;<lpage>196</lpage>.<pub-id pub-id-type="pmid">27580036</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B16">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Gumerov</surname>
<given-names>VM</given-names>
</string-name>, <string-name><surname>Andrianova</surname><given-names>EP</given-names></string-name>, <string-name><surname>Matilla</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Amino acid sensor conserved from bacteria to humans</article-title>. <source><italic toggle="yes">Proc Natl Acad Sci U S A</italic></source>. <year>2022</year>;<volume>119</volume>(10):<comment>e2110415119</comment>.</mixed-citation>
      </ref>
      <ref id="awac081-B17">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Ferron</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Kadurin</surname><given-names>I</given-names></string-name>, <string-name><surname>Dolphin</surname><given-names>AC</given-names></string-name></person-group>. <article-title>Proteolytic maturation of &#x3B1;2&#x3B4; controls the probability of synaptic vesicular release</article-title>. <source>eLife</source>. <year>2018</year>;<volume>7</volume>:<fpage>e37507</fpage>.<pub-id pub-id-type="pmid">29916807</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B18">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Fuller-Bicer</surname>
<given-names>GA</given-names>
</string-name>, <string-name><surname>Varadi</surname><given-names>G</given-names></string-name>, <string-name><surname>Koch</surname><given-names>SE</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Targeted disruption of the voltage-dependent calcium channel &#x3B1;<sub>2</sub>/&#x3B4;-1-subunit</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2009</year>;<volume>297</volume>:<fpage>H117</fpage>&#x2013;<lpage>H124</lpage>.<pub-id pub-id-type="pmid">19429829</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B19">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Patel</surname>
<given-names>R</given-names>
</string-name>, <string-name><surname>Bauer</surname><given-names>CS</given-names></string-name>, <string-name><surname>Nieto-Rostro</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>&#x3B1;2&#x3B4;&#x2212;1 gene deletion affects somatosensory neuron function and delays mechanical hypersensitivity in response to peripheral nerve damage</article-title>. <source>J Neurosci</source>. <year>2013</year>;<volume>33</volume>:<fpage>16412</fpage>&#x2013;<lpage>16426</lpage>.<pub-id pub-id-type="pmid">24133248</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B20">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Li</surname>
<given-names>CY</given-names>
</string-name>, <string-name><surname>Zhang</surname><given-names>XL</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>EA</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Calcium channel &#x3B1;2&#x3B4;1 subunit mediates spinal hyperexcitability in pain modulation</article-title>. <source>Pain</source>. <year>2006</year>;<volume>125</volume>:<fpage>20</fpage>&#x2013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">16764990</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B21">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Faria</surname>
<given-names>LC</given-names>
</string-name>, <string-name><surname>Gu</surname><given-names>F</given-names></string-name>, <string-name><surname>Parada</surname><given-names>I</given-names></string-name>, <string-name><surname>Barres</surname><given-names>B</given-names></string-name>, <string-name><surname>Luo</surname><given-names>ZD</given-names></string-name>, <string-name><surname>Prince</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Epileptiform activity and behavioral arrests in mice overexpressing the calcium channel subunit &#x3B1;2&#x3B4;&#x2212;1</article-title>. <source>Neurobiol Dis</source>. <year>2017</year>;<volume>102</volume>:<fpage>70</fpage>&#x2013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">28193459</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B22">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Schlick</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Flucher</surname><given-names>BE</given-names></string-name>, <string-name><surname>Obermair</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Voltage-activated calcium channel expression profiles in mouse brain and cultured hippocampal neurons</article-title>. <source>Neuroscience</source>. <year>2010</year>;<volume>167</volume>:<fpage>786</fpage>&#x2013;<lpage>798</lpage>.<pub-id pub-id-type="pmid">20188150</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B23">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lee</surname>
<given-names>ST</given-names>
</string-name>, <string-name><surname>Lee</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Bae</surname><given-names>JY</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>CaV &#x3B1;2&#x3B4; autoimmune encephalitis: A novel antibody and its characteristics</article-title>. <source>Ann Neurol</source>. <year>2021</year>;<volume>89</volume>:<fpage>740</fpage>&#x2013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">33415786</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B24">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Park</surname><given-names>KS</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SH</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>IgGs from patients with amyotrophic lateral sclerosis and diabetes target Ca<sub>V</sub>&#x3B1;<sub>2</sub>&#x3B4;1 subunits impairing islet cell function and survival</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2019</year>;<volume>116</volume>:<fpage>26816</fpage>&#x2013;<lpage>26822</lpage>.</mixed-citation>
      </ref>
      <ref id="awac081-B25">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Burashnikov</surname>
<given-names>E</given-names>
</string-name>, <string-name><surname>Pfeiffer</surname><given-names>R</given-names></string-name>, <string-name><surname>Barajas-Martinez</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death</article-title>. <source>Heart Rhythm</source>. <year>2010</year>;<volume>7</volume>:<fpage>1872</fpage>&#x2013;<lpage>1882</lpage>.<pub-id pub-id-type="pmid">20817017</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B26">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Templin</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Ghadri</surname><given-names>JR</given-names></string-name>, <string-name><surname>Rougier</surname><given-names>JS</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6)</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>1077</fpage>&#x2013;<lpage>1088</lpage>.<pub-id pub-id-type="pmid">21383000</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B27">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Hino-Fukuyo</surname>
<given-names>N</given-names>
</string-name>, <string-name><surname>Kikuchi</surname><given-names>A</given-names></string-name>, <string-name><surname>Arai-Ichinoi</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Genomic analysis identifies candidate pathogenic variants in 9 of 18 patients with unexplained West syndrome</article-title>. <source>Hum Genet</source>. <year>2015</year>;<volume>134</volume>:<fpage>649</fpage>&#x2013;<lpage>658</lpage>.<pub-id pub-id-type="pmid">25877686</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B28">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Valentino</surname>
<given-names>F</given-names>
</string-name>, <string-name><surname>Bruno</surname><given-names>LP</given-names></string-name>, <string-name><surname>Doddato</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Exome sequencing in 200 intellectual disability/autistic patients: New candidates and atypical presentations</article-title>. <source>Brain Sci</source>. <year>2021</year>;<volume>11</volume>:<fpage>936</fpage>.<pub-id pub-id-type="pmid">34356170</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B29">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Punetha</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Karaca</surname><given-names>E</given-names></string-name>, <string-name><surname>Gezdirici</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Biallelic CACNA2D2 variants in epileptic encephalopathy and cerebellar atrophy</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2019</year>;<volume>6</volume>:<fpage>1395</fpage>&#x2013;<lpage>1406</lpage>.<pub-id pub-id-type="pmid">31402629</pub-id></mixed-citation>
      </ref>
      <ref id="awac081-B30">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Sch&#xF6;pf</surname>
<given-names>CL</given-names>
</string-name>, <string-name><surname>Ablinger</surname><given-names>C</given-names></string-name>, <string-name><surname>Geisler</surname><given-names>SM</given-names></string-name>, <etal>et al</etal></person-group>
<article-title>Presynaptic &#x3B1;2&#x3B4; subunits are key organizers of glutamatergic synapses</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>:<comment>e1920827118</comment>.</mixed-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>DEE</term>
          <def>
            <p>developmental and epileptic encephalopathy</p>
          </def>
        </def-item>
        <def-item>
          <term>GFP</term>
          <def>
            <p>green fluorescent protein</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>
</pmc-articleset>